Investor Presentaiton slide image

Investor Presentaiton

MACE Supplementary Analyses Supplementary MACE analyses were generally consistent with noninferiority conclusions from the primary analysis, except the ASCEND-ND on-treatment MACE analysis Daprodustat ESA better better No. of Patients Treatment /Total No. asceND D First occurrence Daprodustat 374/1487 DIALYSIS Analysis NI margin = 1.25 Hazard Ratio (95% CI) 0.93 (0.81, 1.07) asceND ND NON-DIALYSIS Analysis Daprodustat better No. of Patients Treatment /Total No. Darbepoetin alfa better NI margin = 1.25 Hazard Ratio (95% CI) 1.03 (0.89, 1.19) MACE (primary) ESA 394/1477 First occurrence Daprodustat 378/1937 MACE (primary) Darbepoetin 371/1935 alfa First occurrence Daprodustat 255/1482 0.96 (0.81, 1.14) First occurrence Daprodustat 274/1937 1.40 (1.17, 1.68) on-treatment ESA 271/1474 on-treatment Darbepoetin 202/1933 MACE MACE alfa First occurrence Daprodustat 363/1487 MACE, excl. 385/1477 0.92 (0.80, 1.07) ESA COVID-19 First occurrence Daprodustat 345/1937 MACE, excl. Darbepoetin 339/1935 alfa 1.03 (0.88, 1.19) COVID-19 MACE First occurrence Daprodustat 326/1487 MACE, until ESA 338/1477 664th MACE 0.6 0.8 1 1.2 1.4 Hazard ratio (95% CI) MACE 0.95 (0.81, 1.10) First occurrence Daprodustat 378/1937 MACE with Darbepoetin 371/1935 additional covariates alfa 1.01 (0.88, 1.17) 0.5 1 1.5 Hazard ratio (95% CI) 2 Note: With the exception of the on-treatment analyses, all analyses follow the "ITT approach" and use both on- and off-treatment MACE events. On-treatment: from treatment start to the earlier of [28 days after the participant's last dose of randomized treatment (last dose date + 28 days), or date of study completion/withdrawal]. HR estimated using a Cox proportional hazards regression model with treatment group, dialysis type (ASCEND-D) or baseline ESA use (ASCEND-ND) and region as covariates. A HR <1 indicates a lower risk with daprodustat compared with ESA/darbepoetin alfa. Cl, confidence interval; ESA, erythropoiesis-stimulating agent; MACE, major adverse cardiovascular event; NI, noninferiority. 14
View entire presentation